MindMed Forms New Board Committee To Evaluate Acquisitions & Scientific Collaborations

Mind Medicine Inc. (MindMed) has formed a Technology Evaluation, Acquisition, and Scientific Integrity Board Committee to identify and expand the company's clinical trial pipeline and IP portfolio of psychedelics. The committee will be advised by Johns Hopkins Professor of Psychiatry and Behavioral Sciences Matthew Johnson, Ph.D. Dr. Johnson is a renowned expert on psychedelics and addiction. He will act as both a senior advisor to the newly formed committee and will also join the company's existing Scientific Advisory Board. In addition, pharma industry veteran and skilled psychiatry clinician Miri Halperin Wernli, Ph.D., MBA, who recently joined . . .